# Jnana Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jnana-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.jnanatx.com
- Total disclosed funding: $155M
- Latest round: Series C (Nov 2, 2022)
- Investors on record: 8

## About

Jnana Therapeutics Inc. is a Boston-based biotechnology company specializing in innovative drug discovery using its proprietary RAPID platform to develop small molecule medicines for various therapeutic targets, focusing on unmet medical needs.Founded in 2017, Jnana Therapeutics Inc. operates out of Boston, US, concentrating on drug discovery processes. The company has engaged in 4 significant deals, with the most recent being an Add-on Trade Sale in August 2024, where Otsuka Pharmaceutical Co., Ltd. acquired Jnana for USD 800 mn. Jnana has raised a total of USD 60 mn to date. The company was co-founded by Abbas Manjee, Hari Kamineni, Shaul Weisband, and Shelley Lavery, with Joanne Kotz serving as CEO.Jnana Therapeutics focuses on innovative drug discovery through its proprietary RAPID platform, which is designed to develop small molecule medicines for a variety of therapeutic targets with enhanced speed and efficiency. The company's primary therapeutic areas include phenylketonuria (PKU) and a range of immune-mediated diseases, addressing significant unmet medical needs. Their chemoproteomics approach enables the identification of unique binding sites on validated protein targets, facilitating the rapid development of new therapeutic candidates. Jnana's sophisticated platform aims to streamline the drug discovery process, ultimately benefiting patients across diverse geographical markets including North America, Europe, and parts of Asia where these diseases are prevalent. With a commitment to advancing first- and best-in-class therapies, Jnana serves a wide array of stakeholders, from pharmaceutical partners to healthcare providers and patients in need of innovative treatment options.Jnana Therapeutics generates revenue through strategic partnerships and collaborations focused on the pharmaceutical sector. The company typically engages in B2B transactions, where it partners with larger pharmaceutical firms to co-develop therapies and share the associated financial risks and rewards. Product offerings, particularly the pipeline therapies derived from their RAPID platform, form the basis of these partnerships, allowing clients to access groundbreaking treatments developed using Jnana's technology. Revenue streams are structured around milestone payments, royalties on future sales, or upfront payments associated with licensing agreements. Jnana reported revenue of USD 19.83 mn for the year 2023.In August 2024, Otsuka Pharmaceutical Co., Ltd. agreed to acquire Jnana Therapeutics Inc. for USD 800 mn, strengthening Otsuka's R&D presence in the Boston biocluster. This acquisition may bolster Jnana's capabilities to launch upcoming products targeting unmet medical needs in the pharmaceutical market. Jnana aims to utilize the recent funding to enhance its drug development efforts and expand its market presence across North America, Europe, and parts of Asia by leveraging Otsuka's extensive network and resources.

## Funding rounds

- Series C, Nov 2, 2022, $60M — Bain Capital, Versant Ventures, Polaris Partners, Avalon Ventures, Pfizer Venture Investments, RA Capital Management
- Series B, Aug 12, 2021, $50M — Versant Ventures, Polaris Partners, Avalon Ventures, Pfizer Venture Investments, AbbVie Ventures, RA Capital Management
- Series A, Dec 14, 2017, $45M — Versant Ventures, Polaris Partners, Avalon Ventures, Pfizer Inc., AbbVie Ventures

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B, Series C
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B, Series C
- Avalon Ventures (https://capitalatlas.ai/funds/avalon-ventures) — Series A, Series B, Series C
- Pfizer Inc. — Series A
- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Series A, Series B
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series B, Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B, Series C
- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series C